132 related articles for article (PubMed ID: 10527522)
21. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites.
Gaus HJ; Owens SR; Winniman M; Cooper S; Cummins LL
Anal Chem; 1997 Feb; 69(3):313-9. PubMed ID: 9030048
[TBL] [Abstract][Full Text] [Related]
22. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
24. Determination of therapeutic oligonucleotides using capillary gel electrophoresis.
Chen B; Bartlett MG
Biomed Chromatogr; 2012 Apr; 26(4):409-18. PubMed ID: 21898474
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
26. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Masarjian L; de Peyster A; Levin AA; Monteith DK
Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
[TBL] [Abstract][Full Text] [Related]
27. Tissue distribution of a menthyl-conjugated oligodeoxyribonucleotide antisense to PAI-1 mRNA.
Szemraj J; Al-Nedawi KN; Chabielska E; Buczko W; Pawlowska Z
Acta Biochim Pol; 2005; 52(4):849-55. PubMed ID: 16302028
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetics of cantide, an antisense oligonucleotide, and its metabolites in rhesus monkeys].
Wang XZ; Wang SH; Song HF; Wang QQ; Wang SQ
Yao Xue Xue Bao; 2011 Nov; 46(11):1370-3. PubMed ID: 22260032
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
31. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
32. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Fitchett JR; Matson JE; Mehta R; Hardee GR; Templin MV; Huang K; Newman MS; Quinn Y; Uster P; Zhu G; Working PK; Horner M; Nelson J; Levin AA
Pharm Res; 1999 Aug; 16(8):1309-15. PubMed ID: 10468036
[TBL] [Abstract][Full Text] [Related]
34. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
Yu RZ; Baker B; Chappell A; Geary RS; Cheung E; Levin AA
Anal Biochem; 2002 May; 304(1):19-25. PubMed ID: 11969184
[TBL] [Abstract][Full Text] [Related]
35. A combined solid phase extraction/capillary gel electrophoresis method for the determination of phosphorothioate oligodeoxynucleotides in biological fluids, tissues and feces.
Wu LX; Lu DD; Zhou Z; Zhang HY; Zhang YL; Wang SQ
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(4):361-8. PubMed ID: 19131282
[TBL] [Abstract][Full Text] [Related]
36. Identification and quantification of GC-rich oligodeoxynucleotides in tissue extracts by capillary gel electrophoresis.
Noll BO; Debelak H; Uhlmann E
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 847(2):153-61. PubMed ID: 17049935
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
38. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
[TBL] [Abstract][Full Text] [Related]
40. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
Watanabe TA; Geary RS; Levin AA
Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
